Introduction
Methods
Patient population
Study protocol
Myocardial contrast echocardiography
Qontrast® evaluation
RTP-ASE visual ischaemia interpretation
SPECT
Statistical analysis
Results
Age | 68 (± 10) |
---|---|
Male | 33 % |
LVEF at rest | 54 (± 11) % |
Previous AMI | 40 % |
Previous PCI | 19 % |
Previous CABG | 13 % |
Heart failure | 13 % |
Hypertension | 48 % |
Valvular surgery | 0 % |
Beta-blocker | 57 % |
ACE inhibitor | 28 % |
ARB | 12 % |
Nitro-glycerine (short acting) | 57 % |
Nitrates (long acting) | 25 % |
Diuretics | 27 % |
Calcium blocker | 18 % |
Sinus rhythm | 93 % |
Dilated left ventricle | 13 % |
Dilated left atrium (n = 43) | 33 % |
Significant valvular disease (n = 43) | 7 % |
Regional WMA/PD at rest | 60 % |
All Territories (n = 201) | LAD (n = 67) | LCx (n = 67) | RCA (n = 67) | Patient (n = 67) | |
---|---|---|---|---|---|
Qontrast® (%) | 30 (15) | 12 (18) | 16 (24) | 2 (3) | 15 (22) |
Vis 1 (%) | 0 | 0 | 0 | 0 | 0 |
Vis 2 (%) | 28 (14) | 11 (16) | 16 (24) | 1 (1) | 22 (33) |
QV | Coronary Territory | Acc (%) | Sens (%) | Spec (%) | PPV (%) | NPV (%) | kappa | AUC |
---|---|---|---|---|---|---|---|---|
A | All |
43
|
39
|
75
|
11
|
94
|
NS
|
0.529 NS
|
A
|
LAD
|
67
|
66
|
75
|
27
|
94
|
0.237 *
|
0.705 NS
|
A | LCx |
29
|
28
|
50
|
6
|
87
|
NS
|
0.229 NS
|
A | RCA |
32
|
28
|
100
|
8
|
100
|
NS
|
0.518 NS
|
β
|
All
|
80
|
83
|
56
|
25
|
95
|
0.249 ***
|
0.678 *
|
β
|
LAD
|
82
|
83
|
75
|
43
|
95
|
0.442 **
|
0.773 *
|
β | LCx |
82
|
94
|
25
|
25
|
94
|
NS
|
0.590 NS
|
β | RCA |
72
|
74
|
50
|
11
|
96
|
NS
|
0.666 NS
|
Axβ
|
All
|
75
|
77
|
63
|
22
|
95
|
0.213 **
|
0.665 *
|
Axβ
|
LAD
|
82
|
83
|
75
|
43
|
95
|
0.442 **
|
0.818 **
|
Axβ | LCx |
90
|
96
|
25
|
33
|
94
|
NS
|
0.404 NS
|
Axβ | RCA |
58
|
57
|
75
|
10
|
97
|
NS
|
0.680 NS
|
A | Patient wise |
35
|
11
|
100
|
29
|
11
|
NS
|
NA
|
β
|
Patient wise
|
60
|
53
|
79
|
38
|
87
|
0.233 *
|
NA
|
Axβ | Patient wise |
47
|
38
|
73
|
31
|
79
|
NS
|
NA
|
Vis 1
|
All
|
93
|
90
|
93
|
59
|
99
|
0.67 ***
|
NA
|
Vis 1
|
LAD
|
87
|
90
|
86
|
53
|
98
|
0.59 ***
|
NA
|
Vis 1
|
LCx
|
94
|
100
|
94
|
56
|
100
|
0.68 ***
|
NA
|
Vis 1
|
RCA
|
96
|
75
|
100
|
100
|
98
|
0.85 ***
|
NA
|
Vis 1
|
Patient wise
|
90
|
89
|
90
|
76
|
96
|
0.75 ***
|
NA
|
Vis 2
|
All
|
92
|
94
|
92
|
55
|
99
|
0.67 ***
|
NA
|
Vis 2
|
LAD
|
86
|
100
|
83
|
53
|
100
|
0.61 ***
|
NA
|
Vis 2
|
LCx
|
94
|
100
|
94
|
57
|
100
|
0.68 ***
|
NA
|
Vis 2
|
RCA
|
95
|
75
|
97
|
60
|
98
|
0.64 ***
|
NA
|
Vis 2
|
Patient wise
|
89
|
91
|
88
|
71
|
97
|
0.73 ***
|
NA
|
No Ischaemia at SPECT | Ischaemia at SPECT | ||||||
---|---|---|---|---|---|---|---|
QV | CA | Rest | Stress | Reserve | Rest | Stress | Reserve |
A | All | 46.9 ± 14.6 | 55.7 ± 10.1 | 1.13 ± 0.60 | 44.3 ± 15.3 | 52.0 ± 9.6 | 1.33 ± 1.26 |
A | LAD | 48.7 ± 9.7 | 56.7 ± 11.7 | 1.05 ± 0.32 | 51.2 ± 7.9 | 51.3 ± 4.9 | 0.86 ± 0.20 * |
A | LCx | 37.1 ± 14.1 | 53.8 ± 6.5 | 1.48 ± 0.91 | 26.0 ± 12.4 | 46.7 ± 1.3 ** | 2.78 ± 2.00 |
A | RCA | 54.9 ± 13.3 | 56.3 ± 10.9 | 0.92 ± 0.28 | 51.5 ± 13.5 | 57.2 ± 17.0 | 0.82 ± 0.34 |
β | All | 1.12 ± 0.41 | 4.7 ± 3.3 | 2.52 ± 1.98 | 1.26 ± 0.38 | 3.2 ± 1.6 ** | 1.55 ± 0.87 * |
β | LAD | 1.15 ± 0.36 | 3.8 ± 1.6 | 1.77 ± 0.75 | 1.28 ± 0.25 | 2.7 ± 1.3 | 1.20 ± 0.59 * |
β | LCx | 1.16 ± 0.47 | 6.4 ± 4.3 | 3.58 ± 2.74 | 1.04 ± 0.26 | 3.9 ± 2.3 | 2.39 ± 1.14 |
β | RCA | 1.04 ± 0.40 | 4.1 ± 2.8 | 2.28 ± 1.59 | 1.51 ± 0.64 | 3.4 ± 1.8 | 1.41 ± 0.65 * |
Axβ | All | 55.7 ± 32.4 | 261 ± 18 | 3.54 ± 4.60 | 59.6 ± 31.5 | 172 ± 100 ** | 2.87 ± 4.13 |
Axβ | LAD | 60.2 ± 26.9 | 222 ± 118 | 2.21 ± 1.38 | 68.0 ± 17.2 | 138 ± 58 ** | 1.11 ± 0.71 * |
Axβ | LCx | 47.0 ± 34.5 | 346 ± 235 | 6.20 ± 7.24 | 28.5 ± 16.7 | 187 ± 111 | 7.91 ± 6.18 |
Axβ | RCA | 60.2 ± 33.7 | 232 ± 166 | 2.53 ± 2.17 | 79.7 ± 45.8 | 222 ± 147 | 1.35 ± 0.85 * |
Total | LAD | LCx | RCA | |
---|---|---|---|---|
Inter-observer (%) Kappa | 91 0.72*** | 88 0.73*** | 97 0.90*** | 88 0.28 NS |
Intra-observer (%) Kappa | 94 0.76*** | 94 0.84*** | 91 0.62*** | 97 0.78*** |